EGFR positive

P2, N=60, Not yet recruiting, Sir Run Run Shaw Hospital

P=N/A, N=30, Active, not recruiting, Massachusetts General Hospital | Trial primary completion date: Dec 2025 --> Dec 2026

Despite intensive treatment with intravenous hydration and zoledronic acid, neurological deterioration occurred; hence, after 25 days of hospitalization, the patient was discharged for home-based palliative care at the family's request. This case highlights the importance of considering metastatic malignancies, particularly breast cancer, in patients with pancreatitis of unclear etiology and severe hypercalcemia.

The most common regimens included capecitabine and everolimus plus exemestane. Multivariable analysis showed that younger age, prior fulvestrant use, and shorter CDK4/6i duration were associated with CHT choice...Treatment decisions are influenced by clinical history and patient characteristics. These findings underscore the need for personalized approaches and molecular profiling to guide post-CDK4/6i therapy in HR-positive/HER2-negative MBC.

Entecavir antiviral therapy led to suppressed viral replication and improved liver function during follow-up. This case emphasizes the need for HBV screening and close monitoring of viral markers/liver function in asymptomatic HBV carriers receiving dalpiciclib, as early antiviral intervention prevents severe liver complications. It also highlights the importance of clinical pharmacist-led medication follow-up management for outpatients receiving targeted anticancer therapy to avoid oversight of comorbidities and associated prophylactic treatment.

After discontinuing the drug and giving continuous norepinephrine to increase BP, the patient's BP returned to stable. This case suggests that although nimotuzumab-related hypotension is mostly mild and reversible, BP monitoring should still be strengthened to maintain vigilance against severe hypotension and intervene promptly in clinical practice.

This prospective real-world analysis shows slightly shorter median PFS and OS times compared with the pivotal trials. Patients in our analyses received alpelisib in later therapy lines, which may explain the poorer outcome.

With this agent, we prepared a dye-panitumumab (Pan) conjugate, (POR-1)3-Pan, for in vivo imaging of epidermal growth factor receptor (EGFR)-positive tumors...Moreover, it enables small tumor nodules (<3 mm) to be visualized clearly. Overall, this study establishes a high-performance NIR dye platform for the development of dye-antibody conjugates for applications in fluorescence image-guided surgery.

To address real-world challenges of missing modality data, a learnable compensation mechanism was implemented, improving model robustness. Our study provides a clinically practical, AI-driven tool for precise risk stratification in HR+/HER2- EBC patients, facilitating individualized treatment and surveillance decisions without reliance on costly multi-omics data.

DeSTIL identifies a subset of HER2+ patients who derive greater benefit from trastuzumab. These findings support the potential of computationally derived immune architecture to inform selection of standard HER2-targeted therapies.

This case suggests that surgical resection following effective systemic therapy may be a treatment option in selected patients with endobronchial oligometastatic breast cancer.

This study confirmed previously known prognosticators within a real-world multicenter Canadian cohort. This included East-Asian ancestry, female sex, and exon19del, which were associated with better overall survival. Future work to better understand the impact of socioeconomic factors and biological reasons for ancestry resulting in different prognosis are needed to better guide treatment management.